Literature Citations: Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century Heated vegetable oils and cardiovascular disease riskfactors Evaluation of the deleterious health effects of consumptionof repeatedly heated vegetable oil n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease:Principles, Practices, Pitfalls, and Promises A Contemporary Review Dietary lipids and risk of autoimmune disease Omega-6 to omega-3 polyunsaturated fatty acid ratio andsubsequent mood disorders in young people with at-risk mental states: a 7-yearlongitudinal study Trans Fat Consumption and Aggression Dietary linoleic acid elevates endogenous 2-AG andanandamide and induces obesity Soybean Oil Is More Obesogenic and Diabetogenic than CoconutOil and Fructose in Mouse: Potential Role for the Liver Omega-6 vegetable oils as a driver of coronary heartdisease: the oxidized linoleic acid hypothesis A host-microbiome interaction mediates the opposing effectsof omega-6 and omega-3 fatty acids on metabolic endotoxemia Marked elevations in pro-inflammatory polyunsaturated fattyacid metabolites in females with irritable bowel syndrome Home use of vegetable oils, markers of systemicinflammation, and endothelial dysfunction among women Relationship of omega-3 and omega-6 fatty acids with semencharacteristics, and anti-oxidant status of seminal plasma: A comparisonbetween fertile and infertile men Dietary fat and risk for advanced age-related maculardegeneration Past Podcast Episode on "Evolutionary Mismatch" Evolutionary Mismatch A nod to our friends in the Amazonthe Tsimane people in all their wisdom Next Level Physical Therapy with Dr
And the next 5 to 10 years, youre going to see paradigm shifts in how psychiatric is going to be treated, without question
Auguste says a patient is unlikely to develop toxicity, as experienced by the 54-year-old man, if theyre taking less than 4,000 IU daily
Thats why injections were used in all the major trials to test the efficacy of GLP-1s: STEP (semaglutide), SURMOUNT (tirzepatide), and SCALE (liraglutide)
Besides, it improved the lipid profile and reduced blood pressure, i.e., much-improved cardiometabolic outcomes, and even its safety profile was comparable to other GLP-1, GIP, and glucagon receptor agonist classes, with reports of only transient gastrointestinal adverse events that were mild or moderate
New dietary reference intakes for macronutrients and fibre
